Eastern Bank maintained its stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,500 shares of the life sciences company’s stock at the end of the second quarter. Eastern Bank’s holdings in Illumina were worth $260,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of ILMN. Columbus Circle Investors acquired a new stake in Illumina during the first quarter valued at approximately $10,121,000. Nisa Investment Advisors LLC boosted its stake in shares of Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock worth $1,056,000 after buying an additional 1,800 shares during the last quarter. DnB Asset Management AS boosted its stake in shares of Illumina by 18.3% in the first quarter. DnB Asset Management AS now owns 16,089 shares of the life sciences company’s stock worth $2,745,000 after buying an additional 2,490 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Illumina during the first quarter worth about $939,000. Finally, Bank of Montreal Can boosted its stake in shares of Illumina by 61.0% in the first quarter. Bank of Montreal Can now owns 113,182 shares of the life sciences company’s stock worth $19,314,000 after buying an additional 42,876 shares during the last quarter. Institutional investors own 93.91% of the company’s stock.
Illumina, Inc. (NASDAQ ILMN) opened at 189.32 on Friday. The stock has a 50 day moving average price of $181.43 and a 200 day moving average price of $174.88. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $199.95. The company has a market cap of $27.64 billion, a PE ratio of 37.99 and a beta of 0.83.
COPYRIGHT VIOLATION WARNING: “Illumina, Inc. (NASDAQ:ILMN) Stake Held by Eastern Bank” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/08/19/illumina-inc-nasdaqilmn-stake-maintained-by-eastern-bank-updated-updated.html.
A number of brokerages have recently issued reports on ILMN. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 target price for the company in a report on Tuesday, May 23rd. Morgan Stanley reiterated an “underweight” rating and set a $115.00 target price (up previously from $108.00) on shares of Illumina in a report on Monday, May 15th. First Analysis upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a report on Wednesday, August 2nd. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $150.00 target price on shares of Illumina in a report on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $177.01.
In other news, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $175.53, for a total value of $2,632,950.00. Following the completion of the sale, the director now directly owns 534,176 shares of the company’s stock, valued at approximately $93,763,913.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Frances Arnold sold 825 shares of Illumina stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $174.77, for a total value of $144,185.25. Following the completion of the sale, the director now directly owns 8,816 shares of the company’s stock, valued at $1,540,772.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 154,010 shares of company stock valued at $27,840,615. Corporate insiders own 1.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.